Grygorii Ursol

5.3k total citations · 1 hit paper
6 papers, 268 citations indexed

About

Grygorii Ursol is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Grygorii Ursol has authored 6 papers receiving a total of 268 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Immunology. Recurrent topics in Grygorii Ursol's work include Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Grygorii Ursol is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Lung Cancer Treatments and Mutations (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Grygorii Ursol collaborates with scholars based in United Kingdom, United States and Spain. Grygorii Ursol's co-authors include Byoung Chul Cho, Farah Louise Lim, Melissa L. Johnson, Alexander Luft, Niels Reinmuth, Jorge Alatorre-Alexander, Xiaojin Shi, Sang‐We Kim, К. К. Лактионов and Tony Mok and has published in prestigious journals such as Journal of Clinical Oncology, Lung Cancer and Clinical Lung Cancer.

In The Last Decade

Grygorii Ursol

6 papers receiving 266 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

2022 238 citations Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Grygorii Ursol

Since Specialization

Citations

This map shows the geographic impact of Grygorii Ursol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grygorii Ursol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grygorii Ursol more than expected).

Fields of papers citing papers by Grygorii Ursol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grygorii Ursol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grygorii Ursol. The network helps show where Grygorii Ursol may publish in the future.

Co-authorship network of co-authors of Grygorii Ursol

This figure shows the co-authorship network connecting the top 25 collaborators of Grygorii Ursol. A scholar is included among the top collaborators of Grygorii Ursol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grygorii Ursol. Grygorii Ursol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study 2024 ·Clinical Lung Cancer ·Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Dmytro Trukhin, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, (unknown), Caitlin D. Lowery, Helen Mann, Solange Peters, Tony Mok, Melissa L. Johnson	2
2	Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) 2023 ·Lung Cancer ·Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medić, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok, Melissa L. Johnson	4
3	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study breakdown → 2022 ·Journal of Clinical Oncology ·Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, К. К. Лактионов, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Xiaojin Shi, Lynne Poole, Solange Peters, Edward B. Garon, Tony Mok, (unknown)	238
4	Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study. 2022 ·Journal of Clinical Oncology ·Likun Chen, Dmytro Trukhin, Oleksii Kolesnik, (unknown), Timuçin Çil, Xingya Li, İrfan Çiçin, (unknown), Yihong Shen, Zhihua Liu, (unknown), Özgür Özyılkan, (unknown), Grygorii Ursol, Jun Chen, (unknown), Zhendong Chen, Helong Zhang, Deniz Tural, (unknown)	3
5	A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. 2022 ·Journal of Clinical Oncology ·Enriqueta Felip, Margarita Majem, Bernard Doger, Timothy Clay, Enric Carcereny, Igor Bondarenko, Julio A. Peguero, Manuel Cobo, Martin Förster, Grygorii Ursol, (unknown), Laia Vilà, Matthew Krebs, Wade T. Iams, Christian Mueller, Frédéric Triebel	18
6	1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II) 2022 ·Research Explorer (The University of Manchester) ·Wade T. Iams, Enriqueta Felip, Margarita Majem, Bernard Doger, Timothy Clay, Enric Carcereny, Igor Bondarenko, Julio A. Peguero, Manuel Cobo, Martin Förster, Grygorii Ursol, Ewa Kalinka‐Warzocha, (unknown), (unknown), Matthew Krebs, (unknown), (unknown), (unknown), Chrystelle Brignone, Frédéric Triebel	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact